Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Jul 20, 2024 | (Q4)Jul 20, 2024 | (Q3)Apr 20, 2024 | (Q2)Jan 20, 2024 | (Q1)Oct 20, 2023 | (FY)Jul 20, 2023 | (Q4)Jul 20, 2023 | (Q3)Apr 20, 2023 | (Q2)Jan 20, 2023 | (Q1)Oct 20, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 12.73%277.94B | 13.41%76.97B | 11.35%94.07B | 13.11%53.71B | 13.87%53.19B | 11.13%246.55B | 3.13%67.87B | 21.38%84.48B | 9.48%47.49B | 8.45%46.71B |
Cost of revenue | 14.00%230.21B | 14.72%66.54B | 12.60%78.02B | 15.78%44.46B | 13.61%41.18B | 12.69%201.94B | 2.91%58B | 23.91%69.29B | 10.95%38.4B | 12.17%36.25B |
Gross profit | 7.01%47.73B | 5.69%10.43B | 5.63%16.05B | 1.84%9.25B | 14.76%12.01B | 4.59%44.61B | 4.47%9.87B | 11.04%15.19B | 3.64%9.09B | -2.72%10.46B |
Operating expense | 6.13%38.38B | 5.50%10.45B | 7.02%9.66B | 5.63%9.26B | 6.44%9.01B | 4.06%36.17B | 7.63%9.9B | 2.42%9.03B | 2.57%8.77B | 3.38%8.47B |
Staff costs | 5.46%22.5B | ---- | ---- | ---- | ---- | -0.34%21.33B | ---- | ---- | ---- | ---- |
Selling and administrative expenses | 9.25%5.26B | ---- | ---- | ---- | ---- | 11.52%4.81B | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 13.22%1.28B | ---- | ---- | ---- | ---- | 21.71%1.13B | ---- | ---- | ---- | ---- |
-General and administrative expense | 8.04%3.98B | ---- | ---- | ---- | ---- | 8.74%3.68B | ---- | ---- | ---- | ---- |
Depreciation and amortization | -2.89%1.28B | ---- | ---- | ---- | ---- | 12.86%1.32B | ---- | ---- | ---- | ---- |
-Depreciation | -2.89%1.28B | ---- | ---- | ---- | ---- | 12.86%1.32B | ---- | ---- | ---- | ---- |
Rent and land expenses | 2.22%1.15B | ---- | ---- | ---- | ---- | 9.84%1.13B | ---- | ---- | ---- | ---- |
Other operating expenses | 8.19%8.2B | ---- | ---- | ---- | ---- | 10.76%7.58B | ---- | ---- | ---- | ---- |
Operating profit | 10.78%9.35B | 43.24%-21M | 3.60%6.39B | -102.51%-8M | 50.08%2.99B | 6.92%8.44B | -115.23%-37M | 26.65%6.16B | 45.00%319M | -22.22%2B |
Net non-operating interest income (expenses) | 1,350.00%58M | 88.89%17M | 320.00%21M | 900.00%8M | 233.33%12M | 111.76%4M | 9M | 183.33%5M | 92.86%-1M | 35.71%-9M |
Non-operating interest income | 84.38%118M | 40.00%35M | 113.33%32M | 92.31%25M | 136.36%26M | 156.00%64M | 150.00%25M | 200.00%15M | 160.00%13M | 120.00%11M |
Non-operating interest expense | 0.00%60M | 12.50%18M | 10.00%11M | 21.43%17M | -30.00%14M | 1.69%60M | 60.00%16M | -9.09%10M | -26.32%14M | 5.26%20M |
Net investment income | 23.30%471M | 41.61%211M | -76.92%3M | 16.81%139M | 16.83%118M | 22.04%382M | 577.27%149M | -31.58%13M | 14.42%119M | -39.88%101M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 92.21%148M | -22.11%148M | 0 | -46.15%77M | 32.87%190M | -78M | ||||
Income from associates and other participating interests | -29.27%87M | -450.00%-14M | -7.55%49M | -36.00%16M | -12.20%36M | 44.71%123M | 113.79%4M | 17.78%53M | 31.58%25M | -18.00%41M |
Special income (charges) | 5.88%-64M | 3.13%-31M | 41.94%-18M | -124.14%-7M | 76.47%-8M | 51.08%-68M | 58.97%-32M | -342.86%-31M | 226.09%29M | -9.68%-34M |
Less:Other special charges | -85.42%7M | ---- | ---- | ---- | ---- | 1,500.00%48M | --16M | --27M | ---- | ---- |
Less:Write off | 185.00%57M | 50.00%24M | 350.00%18M | 120.59%7M | -76.47%8M | -85.29%20M | -78.67%16M | -42.86%4M | -247.83%-34M | 9.68%34M |
Other non-operating income (expenses) | -4.08%235M | -21.18%67M | -37.29%37M | 24.32%46M | 32.81%85M | 183.90%245M | 214.86%85M | 150.86%59M | 126.06%37M | 60.00%64M |
Income before tax | 11.74%10.28B | 1.64%371M | 4.72%6.48B | -60.57%194M | 50.02%3.24B | 15.51%9.2B | 64.41%365M | 28.81%6.18B | 500.00%492M | -24.51%2.16B |
Income tax | 16.48%3.24B | 143.80%60M | 6.94%2.08B | -55.11%101M | 33.51%996M | -10.59%2.78B | -176.54%-137M | 1.46%1.95B | 74.42%225M | -15.52%746M |
Net income | 9.67%7.04B | -38.25%310M | 3.73%4.4B | -65.30%93M | 58.78%2.24B | 32.20%6.42B | 1,067.44%502M | 46.98%4.24B | 670.21%268M | -28.58%1.41B |
Net income continuous operations | 9.69%7.04B | -38.05%311M | 3.70%4.4B | -65.17%93M | 58.74%2.24B | 32.20%6.42B | 1,067.44%502M | 46.98%4.24B | 668.09%267M | -28.53%1.41B |
Noncontrolling interests | -14.81%46M | -5.88%16M | -13.79%25M | -112.50%-1M | 6M | -85.79%54M | 312.50%17M | 161.70%29M | 123.53%8M | 0 |
Net income attributable to the company | 9.90%7B | -39.05%295M | 3.82%4.37B | -63.85%94M | 58.36%2.24B | 42.19%6.37B | 830.77%484M | 43.64%4.21B | 2,100.00%260M | -6.30%1.41B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 9.90%7B | -39.05%295M | 3.82%4.37B | -63.85%94M | 58.36%2.24B | 42.19%6.37B | 830.77%484M | 43.64%4.21B | 2,100.00%260M | -6.30%1.41B |
Gross dividend payment | ||||||||||
Basic earnings per share | 9.81%710.86 | -39.16%29.92 | 3.75%444.15 | -64.18%9.46 | 58.22%227.33 | 42.00%647.35 | 864.31%49.18 | 43.43%428.08 | 1,946.85%26.41 | -6.54%143.68 |
Diluted earnings per share | 9.81%710.86 | -39.16%29.92 | 3.73%444.0528 | -64.18%9.46 | 58.22%227.33 | 42.00%647.35 | 864.31%49.18 | 43.43%428.08 | 1,946.85%26.41 | -6.54%143.68 |
Dividend per share | 15.79%220 | 15.79%220 | 0 | 0 | 0 | 35.71%190 | 35.71%190 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |